Journal · Updated 2026-08-11

Cheapest Compounded Semaglutide Online in 2026: Every Real Price, In Words

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

What compounded semaglutide is

Semaglutide is a GLP-1 receptor agonist — a single-pathway incretin drug, unlike tirzepatide's dual GIP-plus-GLP-1 action — that Novo Nordisk sells as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral tablet. In STEP 1, the pivotal 68-week obesity trial published in the New England Journal of Medicine in 2021, participants on 2.4 mg weekly lost an average of 14.9 percent of body weight against 2.4 percent with placebo. A compounded version is the same intended molecule prepared to order by a 503A pharmacy from bulk active ingredient, typically dispensed as a multi-dose vial you draw yourself — and, by statute, never FDA-approved, never reviewed for safety, effectiveness, or quality before it ships. The FDA has specifically warned about products built on semaglutide sodium and semaglutide acetate salt forms, which it considers different active ingredients from the base semaglutide in the approved drugs; asking your pharmacy, in writing, which form it uses is one of the highest-value questions in this market.

Every rankable price, in words

Cheapest first, all-in at the 2.4 mg maintenance basis. bmiMD holds one hundred twenty-nine dollars a month on its monthly plan, stepping down to one hundred nineteen on three months, one hundred nine on six, and ninety-nine on twelve — the same price at every dose, with the price varying by plan length rather than by dose, per two independent July 2026 captures. HealthRX publishes ninety-nine on its twelve-month plan and one hundred thirty-three on its three-month plan, with no month-to-month rate at all. Trimi's annual plan works out to ninety-nine a month but bills as eleven hundred eighty-eight dollars up front — the lowest committed figure and the highest concentrated risk in the market. Oak Longevity holds one hundred thirty-three month-to-month, a small operator whose pharmacy partner is not publicly itemized. NexLife's promotional card runs one hundred thirty-nine monthly, one hundred thirty-two on three months, one hundred twenty-five on six, and one hundred nineteen on twelve, all-inclusive with a Flat Forever lock-in through August 31, 2026 (standard card one hundred sixty-five monthly). Yucca Health advertises one hundred forty-six as a new-patient six-month-plan rate under its lifetime promo code, with full pricing gated behind intake. OrderlyMeds and Ivim Health sit at one hundred forty-nine — Ivim's figure already containing its seventy-five-dollar membership. TMates reaches one hundred fifty-eight on a twelve-month plan against two hundred forty-nine month-to-month. From there the market steps through Lavender Sky at one hundred seventy-four, Fridays at one hundred seventy-five, Mochi at one hundred seventy-eight once its seventy-nine-dollar membership is counted, Henry Meds and Gala at one hundred seventy-nine, Eden at one hundred ninety-eight all-in, SkinnyRx and Noom Med and Care Bare Rx around one hundred ninety-nine, Enhance MD's bundled program at two hundred twelve, ShedRx at two hundred forty-nine, and on up to LifeMD's three hundred forty-eight at the ceiling.

Two kinds of figures are deliberately absent from that ranking. Strut Health's ninety-nine-dollar sublingual price is the cheapest entry number in the whole market — and it is a lowest-dose auto-refill start price with no published maintenance figure, which our methodology cannot rank. And Sprout Health's one-forty-nine and Synergy Rx's one-ninety-nine are advertised "starting at" figures whose real ongoing rate is personalized inside the enrollment funnel; both are recorded, neither is ranked.

The twelve-month arithmetic

A year of the cheapest rankable semaglutide totals one thousand one hundred eighty-eight dollars — reachable three ways with three different risk profiles: bmiMD's twelve-month plan billed monthly (leave-able, though the rate assumes the term), HealthRX's twelve-month plan billed monthly, or Trimi's annual plan with the entire sum charged on day one. A year of bmiMD billed strictly month-to-month is one thousand five hundred forty-eight. A year of NexLife's promotional twelve-month plan is one thousand four hundred twenty-eight. A year of Mochi, memberships included, is two thousand one hundred thirty-six. And a year of FDA-approved Wegovy pens at the standard three-forty-nine price is four thousand one hundred eighty-eight — though a new patient stacking the one-ninety-nine two-fill introduction and considering oral Wegovy from one forty-nine can bring a first brand year meaningfully below that. The spread between the cheapest compounded year and the standard brand year is roughly three thousand dollars; the oral-Wegovy route narrows it to under a thousand for patients whose dose stays in the entry tiers.

Compounded versus Wegovy: the honest comparison

What the brand premium buys is the same as on the tirzepatide side: an FDA-reviewed product, a sealed pen instead of vial-and-syringe math, trial evidence that applies to the exact product dispensed, and zero exposure to compounding-market legal weather. What makes the semaglutide decision different is that the brand floor is lower and falling — a one-forty-nine oral tablet and a one-ninety-nine introductory pen put FDA-approved semaglutide within about fifty dollars a month of the compounded floor for a new patient's first several months, a gap that simply doesn't exist on tirzepatide, where brand maintenance is four hundred forty-nine. If your clinician is indifferent between molecules and your budget is the constraint, the strongest cases in the whole GLP-1 market right now are cheap compounded semaglutide at ninety-nine to one twenty-nine, or brand oral Wegovy at one forty-nine. Run the choice with a prescriber, and run the seven-point safety checklist against any compounded program before paying — prescription required, named pharmacy verified on your state board lookup, certificate of analysis, base-form semaglutide rather than a salt, cold-chain shipping, sane beyond-use dating, and screenshot-the-checkout exit terms.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.